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Abstract
Accelerated heart rate is a risk factor of general and cardiovascular mortality in different populations. The classical 
treatment to achieve heart rate reduction by beta-blockers and calcium channel antagonists from the group of non- 
-dihydropyridines (verapamil and diltiazem), is often limited by contraindications or adverse reactions. Ivabradine is 
a unique, modern drug which mechanism of action is blocking the If current in the sinoatrial node. This translates into 
a reduction in heart rate — a parameter associated with poor prognosis in patients with heart failure (HF). The following 
document contains the opinion of an expert group summarizing current knowledge on ivabradine and its use in popula-
tion of patients with HF.
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Introduction
Heart failure (HF) is currently one of the most serious health 
problems in Poland. It is estimated that about one million 
people may suffer from HF in Poland, and the number of 
new cases is estimated at 220,000 per year [1]. Worldwide, 
HF is a global public health problem affecting 23 million 
people. In the United States, the prevalence of HF is esti-
mated at 5.7 million [2]. Among the countries represented 
in the European Society of Cardiology (ESC), the number of 
patients with HF is about 15 million [3].
Considering that HR is caused by pathologies such as 
coronary artery disease, hypertension, diabetes mellitus or 
obesity, as well as by the growing population of elderly people, 
it can be concluded that there will be a significant increase 
in patients with heart failure. The risk of HR in the European 
population at the age of 55 is 33% for men and 29% for wo-
men, after the age of 85 it equals 17.4% for both sexes [4, 5].
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of patients with HF by 25% over the next 20 years, the 
associated treatment costs will increase twice.
Optimal heart rate — the aim  
of cardiac therapy
Accelerated heart rate (HR, heart rate) is one of the basic 
and early symptoms of HF. It correlates with the severity of 
the disease regardless of its etiology, being a recognized 
symptom of prognostic value. Only acceleration of heart 
rate, if it is significant and lasts long enough, may worsen 
the contractility and become the sole cause of HF. This 
condition is defined by tachyarrhythmic cardiomyopathy, 
which according to the current classification belongs to 
the group of primary acquired cardiomyopathies [9]. Ta-
chycardia is also a recognized disrupter of the ventricular 
inflow and exacerbates symptoms of diastolic dysfunction 
or heart failure with preserved ejection fraction (HFpEF). 
Ischemia provoked by insufficiently controlled HR can lead 
to myocardial hibernation and reversible deterioration of 
ventricular systolic function.
According to numerous studies, both cardiovascular 
mortality and total mortality in patients with HF are directly 
proportional to HR.
Key data defining HR ≥ 70 bpm associated with poorer 
prognosis obtained  in the BEAUTIFUL study which involved 
typically treated population with ischemic left ventricular 
dysfunction. What is extremely important — a decrease in 
HR allows to reduce mortality. This has become the basis for 
the use of drugs, thanks to which HR is a parameter which 
is relatively easy to modify influencing the prognosis in HF.
The results of numerous clinical trials have confirmed 
the high therapeutic efficacy of decrease in HR in HF — ini-
tially achieved only with beta-adrenolytic drugs. HR change 
is not the only element of beta-adrenolytic action — apart 
from chronotropically negative effect, the effect of blocking 
the activation of adrenergic system causes reduction of 
dangerous cardiac arrhythmias, reduction of ischemia and 
post-infarction myocardial damage and counteracts left 
ventricular remodeling. HR achieved during treatment is 
also a good indicator of its effectiveness. Meta-analysis of 
McAlister and his team based on data from 23 studies on 
systolic HF showed that the degree of HR decrease, rather 
than the dose of beta-adrenolytic, correlates with clinical 
benefits. With an average 24% reduction in mortality ac-
ross the group, HR decrease of 5 bpm (but not reaching 
a specific dose of the drug) was shown to reduce mortality 
by 18% [10]. This strong evidence of reduced mortality in 
patients with HF in NYHA class II–IV and reduced risk of 
other key complications makes beta-adrenolytics the first 
line of treatment in systolic HF and is recommended to-
gether with angiotensin-converting enzyme (ACE) inhibitors 
in all patients with left ventricular ejection fraction (LVEF) 
Despite the significant progress in medicine, the pro-
gnosis in HF is still serious. In 5 years post diagnosis 60% 
of men and 40% of women die. Mortality of the entire po-
pulation of patients with HF, regardless of etiology, is about 
10% per year. The number of patients with this disease 
is 2.5 times higher than the number of patients with all 
cancers combined. Every day 117 Poles die of HF, which 
means 43,000 deaths per year [6]. Half of the patients 
die within 5 years of the diagnosis of the disease. These 
statistics are significantly worse than in the case of breast, 
ovarian or prostate cancer. Therefore, every effort should 
be made to improve the prognosis by comprehensive, up 
to date treatment.
Hospitalization in HR — economic aspects
The annual costs of treatment of patients with HF in Poland 
increased to 1.7 billion PLN and already account for 3.2% of 
the National Health Fund (NFZ) budget [1]. According to the 
data of the Institute of Health Care Management, in 2009 all 
diagnoses within HF constituted 7.17% of total hospitaliza-
tion among women over 65 years of age and 6.77% among 
men over 65 years of age [7]. In 2012, the National Health 
Fund financed services for patients treated for HF spending 
over 672 million PLN [7]. The largest amount was spent on 
hospital services — 635 million PLN (94%), followed by the-
rapeutic rehabilitation — 26 million PLN (4%) and outpatient 
specialist care — 10 million PLN (2%). The share of these 
costs in the total provision was 2.2% in the case of hospital 
treatment, 1. 3% in the case of rehabilitation and 0. 2% in 
the case of outpatient specialist care [7].
Heart failure is the most common cause of hospitaliza-
tion among people over 65 years of age. In 2012, the NHF 
accounted for the treatment of this disease in the group 
of 288,000 patients in total, 158,000 of whom were over 
69 years of age [7]. Emergency admissions concerned 
almost 83% of the total number of admissions. In 2012 in 
Poland 187,000 patients were admitted to hospital for HF 
and every fourth patient was hospitalized again in less 
than 30 days after discharge. 
Poland was ranked first among 30 Organization 
for Economic Co-operation and Development (OECD) 
countries  in terms of the number of hospitalizations 
due to HF, being ahead of the United States, Germany 
and Austria [8]. The number of hospitalizations in our 
country is twice as high as the OECD average. In 2012, 
the costs related to hospitalization of 187,500 patients 
amounted to PLN 635 million, which gives an average of 
about PLN 3,400 per year per patient. The mean period 
of hospitalization of patients with HF (group E53; HF in 
patients > 69-years-old or with complications and coe-
xisting diseases) in Poland in 2012 was 6 days (median) 
[7]. It is estimated that with an increase in the number 
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< 40% in order to reduce the frequency of hospitalization 
due to HF and the risk of premature mortality. Impor-
tantly, the recommendations do not recognize the class 
effect and apply to drugs tested in prospective clinical 
trials – metoprolol extended-release, bisoprolol, carvedilol 
and — despite the lack of full evidence of reduced overall 
mortality — nebivolol.
However, the common use of beta-adrenolytics is asso-
ciated with the risk of adverse effects, common in patients 
with HF. This is the main reason for under-dosing or not in-
cluding this group of drugs to the treatment regimen, despi-
te the obvious benefits. Among the most common causes 
are hypotonia, exacerbation of intermittent claudication 
or bronchospastic symptoms. In a certain percentage of 
cases, the use of beta-adrenolytics, even at the right dose, 
is expressed by deterioration of respiratory parameters. 
Although beta2 receptors dominate in the smooth muscles 
of the bronchial tree, it is estimated that the percentage 
of beta1 receptors reaches 20% and therefore the use of 
beta1 selective preparations may cause exacerbation of 
asthma and chronic obstructive pulmonary disease. This 
leads to a confirmed therapeutic gap — only 22% of Polish 
patients with HF take the optimal dose of beta-adrenolytic, 
and 23% do not receive it at all [11]. Also, data from the 
DATA HELP register indicate that HR median of Polish 
patients with HF exceeds 70 bpm [12, 13]
Undoubtedly, the most sensitive period after discharge 
are the first few weeks, when the risk of death and re-
-hospitalization due to HF is the highest [14]. Studies show 
that in both cases the risk was highest within one month 
of discharge and then it gradually decreased, especially 
in respect to deaths due to progress of HF and sudden 
cardiac death.
The longer the patient has been hospitalized, the 
higher the risk of death (which is probably associated 
with more advanced HF) and the more hospitalizations he 
has experienced in the past. Unfortunately, a significant 
number of patients discharged from the hospital after HF 
exacerbation still have an increased heart rate [15].
Out of the group evaluated in the OPTIMIZE-HF 
register, only 73% of individuals discharged from the 
hospital were treated with beta-adrenolitics. In pa-
tients without beta-adrenolytic therapy, HR median was 
80 bpm (IQR 70–89 bpm), in comparison to HR 78 bpm 
(IQR 69–88 bpm) in patients with < 25% target dose, 
HR 74 bpm (IQR 66–82 bpm) in patients with 25–49% 
target dose, HR bpm (IQR bpm) in 55–99% target dose 
and HR of 72 bpm (IQR 65–80 bpm) in patients in whom 
the 100% target dose of beta-adrenolytic acid has been 
reached. Data from this register show that 71% of pa-
tients are discharged from the hospital with a heart rate 
≥ 70 bpm, 63% of whom are discharged with ≥ 50% of 
the target dose of beta-adrenolytic acid. Unfortunately, 
which was also confirmed in the OPTIMIZE-HF register, 
further optimization of the dose of beta-adrenolytic drugs 
in ambulatory conditions does not take place. According 
to the data from the cited register, after 60 and 90 days 
after discharge 70–75% of patients (depending on the 
type of beta-adrenolytic therapy) took the same dose of 
the drug prescribed when discharged from the hospi-
tal, and in 9–13% of patients the dose was reduced in 
relation to the discharge. Only in about 15% of cases 
an attempt was made to increase and further optimize 
beta-adrenolytic treatment. After 60 and 90 days after 
discharge, only 17.5% and 7.9% of patients were treated 
with the target dose of beta-adrenolytic, respectively [16]. 
Therefore, especially those who have been hospitalized 
due to HF should receive optimal treatment at the time 
of discharge to modify the further course of the disease, 
including a correspondingly reduced heart rate. Any re-
-hospitalization may indicate the ineffectiveness of the 
current treatment scheme/strategy and repeating it with-
out changes (including adequate modification of heart 
rate) does not guarantee that re-hospitalization will not 
be avoided.
The QUALIFY registry, which is an international pro-
spective observational study of 7,092 patients with 
HF who have been hospitalized for HF in the period of 
1–15 months prior to including them into the study. The 
study analyzed how many patients, after discharge from 
the hospital, follow the recommendations for the use of 
ACE inhibitors, beta-adrenolytics, sartans, aldosterone 
and ivabradine antagonists. The results showed that 67% 
of patients follow the recommendations in a good level, 
25% as moderate level and 8% in bad level. According to 
Polish QUALIFY registry data, for ACE inhibitors only 27% 
of outpatient patients reached the target dose, for sartans 
— 4%, beta-adrenolytics — 17.7%, and for aldosterone 
antagonists — 66% [17]. Compared to global data, Polish 
patients of the QUALIFY registry are more often treated with 
the recommended standard drug groups (ACE inhibitors/ 
/sartans, beta-adrenolitics and aldosterone antagonists) 
except for ivabradine (33% baseline results in the world 
vs. 13.9% in Poland) [17]. Every third patient in the world 
is treated with ivabradine, whereas in Poland it is used in 
every seventh outpatient patient with HF, although 25% of 
the Polish population of the QUALIFY registry had a sinus 
rhythm with a frequency greater than or equal to 75 bpm 
[17]. Moreover, only 39.2% of patients achieved a resting 
heart rate below 70 bpm.
These data show that in Poland we do not make use 
of the possibilities of optimizing the therapy of patients 
with HF in the context of the possibility of decreasing the 
heart rate. They also prove that using all recommended 
therapies in everyday practice, including ivabradine, is 
the only way for further improving the prognosis in this 
difficult group of patients. It is also worth emphasizing that 
ivabradine dosage is not complicated, it requires rhythm 
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analysis in electrocardiogram and heart rate control in 
order to determine the dosage. This should be performed 
by a GP or a cardiologist working in an out-patient clinic.
Ivabradine — drug characteristics
Pharmacological action of the drug
Ivabradine belongs to a new class of drugs that selectively 
slow down heart rate. The mechanism of its action is a se-
lective and specific inhibition of the ionic current in the sinus 
node cells [18]. They are part of a group of pacemaker cells, 
which have the ability to spontaneously generate action 
potentials. Four types of membrane channels and the ionic 
currents flowing through them, including the pacemaker cur-
rent flowing through a channel takes part in the automatic 
mechanism of pacemaker cells. Channel f belongs to the 
family of ionic HCN channels (hyperpolarization-activated 
cyclic nucleotide-gated channel), presence of which was 
found only in the heart, in some parts of the brain and in the 
retina of the eye. The fact that the occurrence of the current 
If is initiated by hyperpolarization, makes it so unusual that 
when it was detected in 1979, it was called funny. Until then, 
it was believed that ion channels in myocardial cells were 
only activated by depolarization of the cell membrane [19].
Channels f are also directly activated by molecules of 
cyclic adenosine-3’-5’-monophosphate (cAMP), which are 
inside the cells. Stimulation of beta-adrenergic receptors 
leads to activation of adenylate cyclase, which causes an 
increase in cAMP concentration, which leads to activation 
of the If current, shortening of depolarization diastolic 
time, shortening of the diastolic phase and acceleration 
of heart rate [4, 20, 21].
Thus, as a result of blocking the f canal, resting depo-
larization of the sinus node during the period of diastole 
occurs, as a result the heart rate slows down. Ivabradine 
acts exclusively on the sinus node and does not affect the 
conduction time in the atrium, atrioventricular node or 
ventricles, nor does it affect the contractility of the heart 
muscle (except for effects caused by slowing down heart 
rate) or ventricular repolarization. It is commonly believed 
that it also has insignificant and clinically irrelevant influ-
ence on blood pressure [22, 23].
Although no significant influence of ivabradine on the 
duration of the corrected QT or PR interval has been ob-
served in preclinical studies [24], in some people, the use 
of ivabradine and associated slow heart rate may increase 
the prolongation of the QT interval. Therefore, caution 
should be exercised or the use of ivabradine should be 
avoided in patients with long QT syndrome or those taking 
drugs that prolong the QT interval [23].
The selective action of ivabradine on the sinus node 
is a unique feature among drugs used to slow down 
heart rate. Other substances, including beta-adrenolitics, 
nondihydropyridine calcium channel blockers (verapamil 
and diltiazem), amiodarone or digoxin, have a hypotensive 
effect they reduce myocardial contractility and have pro-
arrhythmic effects, which in patients with HR is a significant 
limitation of their use [13].
In the recommended doses ivabradine slows down the 
heart rate at rest and during exercise by about 10 bpm. Its 
blocking power increases with heart rate, so the higher the 
heart rate before treatment, the greater the therapeutic 
effect [18]. This drug increases the ejection heart volume, 
which means that the minute capacity of the heart remains 
unchanged when it is slowed down. This is a distinguishing 
feature of ivabradine from beta-adrenolitics, which by redu-
cing heart contractility leads to a decrease in its ejection 
and minute capacity [25, 26]. Although the f-channels are 
also present in the lower parts of the myocardium, they re-
main inactive under physiological conditions, so ivabradine 
reduces the heart rate only in patients with sinus rhythm 
[25]. It is worth emphasizing that ivabradine has the abi-
lity to bind to channel f only when it is open. Therefore, it 
connects more effectively to its place of bonding when the 
cycles of closing and opening of the f canal occur quickly, 
i.e. — as mentioned above — when the heart rate is higher. 
On the other hand, thanks to this property, the slower the 
HR is, the less effective the drug is, and as a result the 
risk of severe bradycardia is reduced [27].
Pharmacokinetics and pharmacodynamics
After oral administration, ivabradine is quickly and almost 
completely absorbed from the gastrointestinal tract. Tmax 
when administered in fasting state is 1 hour. Due to the 
effect of the first passage in the intestines and liver, 
bioavailability is about 40%. Food delays drug absorption 
by nearly 1 hour and increases the exposure on it in the 
plasma by 20–30%. Ivabradine binds to plasma proteins 
in about 70%. It is metabolized in the liver and intestines 
by oxidation exclusively by the cytochromes P-450, CYP3A4 
isoenzyme. The main active metabolite is the N-demethyl 
derivative. Exposure to this substance corresponds to 
approximately 40% of exposure to the parent substance. 
Metabolism of this active metabolite also occurs with 
the isoenzyme CYP3A4. Ivabradine has a low affinity to 
CYP3A4, has no clinically significant stimulant or inhibi-
tory effect on this isoenzyme and is therefore considered 
unlikely to affect the metabolism of other substrates or 
plasma concentrations of these substances. Conversely, 
CYP3A4 potent inhibitors or stimulants may have a signi-
ficant effect on plasma ivabradine concentrations. T1/2 in 
the elimination phase is 2 h, and the effective t1/2 is 11 h. 
Metabolites are excreted at a similar percentage with feces 
and urine; about 4% of the dose is excreted with urine in 
the unchanged form. Elderly age and renal dysfunction do 
not affect the pharmacokinetics of the drug. In patients 
with moderate hepatic impairment, concentrations of 
ivabradine and its main metabolite are about 20% higher 
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However, it should be remembered that CYP3A4 inhibi-
tors increase plasma concentrations of ivabradine, while 
substances stimulating this isoenzyme decrease these 
concentrations. Increased plasma concentrations of iva-
bradine may cause a risk of severe bradycardia. Therefore, 
parallel use of ivabradine with strong CYP3A4 inhibitors, 
such as: azole antifungal agents (fluconazole, itracona-
zole, ketoconazole), macrolide antibiotics (erythromycin, 
josamycin, clarithromycin, telithromycin), HIV protease 
inhibitors (nelfinavir, ritonavir) and nefazodone is contra-
indicated. Strong CYP3A4 inhibitors such as ketoconazole 
(200 mg/24 h) and josamycin (1 g 2 ×/24 h) increase the 
mean plasma exposure to ivabradine by 7–8 times. Parallel 
use of ivabradine with QT prolonging drugs, e.g. quinidine, 
disopyramide, bepridil, sotalol, ibutilide, amiodarone, pi-
mozide, ziprasidone, sertindole, mefloquine, halofantrine, 
pentamidine, cisapride, erythromycin intravenous (i.v.) is 
not recommended. If this association is necessary, the 
heart function should be closely monitored. The combina-
tion of ivabradine with diltiazem or verapamil resulted in 
an increase in plasma concentrations and an additional 
reduction in heart rate of 5 bpm, so it is not recommen-
ded to use these drugs in parallel. The consumption of 
grapefruit juice during treatment with ivabradine doubles 
its power, so its consumption during treatment should 
be reduced. CYP3A4 stimulants, including rifampicin, 
barbiturates, phenytoin and St. John’s wort preparations, 
may reduce plasma concentrations of ivabradine and thus 
impair its effect [23].
Site and dosage of ivabradine  
in chronic heart failure
Since 2012, we can use a new drug with a unique effect, 
thanks to which, according to the results of the SHIFT 
study, it is possible to reduce the risk of hospitalization of 
patients with HR by 26% and to reduce the risk of death 
due to HR by as much as 26% [30, 31]. Treatment with 
ivabradine should be initiated in individuals with stable 
HR who, despite standard treatment (i.e. ACE inhibitor or 
angiotensin II receptor antagonist in case of intolerance of 
the 1st one, beta-adrenolytic and mineralocorticoid recep-
tor antagonist) we may observe maintained symptoms of 
class II–IV in NYHA, LVEF ≤ 35%, the patient has a sinus 
rhythm and a HR of ≥ 70 bpm (Figure 1) [32]. The admi-
nistration of ivabradine in the above mentioned group of 
patients may also be considered in patients intolerant to 
beta-adrenolytics [32].
Looking at the algorithm shown in Figure 1, it is worth 
suggesting the following practical advice:
 — priority for CRT usage should be given to patients with 
left bundle branch block and QRS > 150 ms (this group 
uses this form of therapy the most);
 — priority for usage of ivabradine should be given to 
patients with sinus rhythm and HR ≥ 75 ppm despite 
than in patients with normal liver function. The drug is 
contraindicated during pregnancy and breastfeeding, and 
women of childbearing age must use effective methods 
of contraception during therapy [23]. It is also possible to 
administer ivabradine intravenously, but currently there is 
no parenteral form of this drug [28].
Indications
Since 2005 ivabradine has been used in the symp-
tomatic treatment of chronic stable angina pectoris in 
patients with ischemic heart disease and normal sinus 
rhythm. It is recommended in patients with intolerance 
or with contraindications for the use of beta-adrenolitics.
Since 2009, following the ASSOCIATE study, it has been 
allowed to be used in combination with beta-adrenolytics in 
individuals who have not been adequately controlled with 
an optimal dose of beta-adrenolytic and whose heart rate 
is higher than 70 ppm.
In February 2012, following the announcement of the 
SHIFT results, another indication appeared in the form 
of chronic HR in class II–IV according to the NYHA classi-
fication, with systolic dysfunction, in patients with sinus 
rhythm, with a heart rate of ≥ 75 bpm, in combination with 
standard treatment, including beta-adrenolytic treatment, 
or when beta-adrenolytic treatment is contraindicated or 
not tolerated [23].
Adverse effects
Ivabradine is considered safe, rarely causes side effects, 
and if they occur, they are usually harmless. The most 
common are visual impairment (may affect about 14.5% 
of treated patients), described as transient sensations of 
strong light in part of the field of vision (usually caused by 
sudden changes in light intensity; they usually occur during 
the first 2 months of treatment). Slightly less (1–10% of 
patients) frequent are: blurred vision, bradycardia (espe-
cially in the first 2–3 months, including 0.5% of patients 
with severe bradycardia < 40 thighs per minute), 1st degree 
atrioventricular block, ventricular extrasystoles, headaches 
(mainly in the first month of treatment), dizziness (probably 
related to bradycardia) and additional atrial extrasystoles. 
Due to the ability of ivabradine to bind to channel f only 
when it is open, i.e. as a result of weaker action at a slower 
heart rate, as described above, the heart rate cannot be 
decreased by more than 18–20% of its initial value [27, 29]. 
An additional protection is the fact that when ivabradine 
is used at a dose of 20 mg twice daily, its action initially 
increases and then reaches the plateau [23].
Interactions
Ivabradine is metabolized exclusively by the cytochromes 
P-450, CYP3A4 isoenzyme and is a very weak inhibitor of 
this isoenzyme, so it does not affect the metabolism of 
other CYP3A4 substrates and their plasma concentrations. 
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the optimal dose of beta-adrenolytic or in case of in-
tolerance or in case of contraindication for its usage;
 — priority for introducing ARNI instead of ACE inhibitors 
used till now should be given to patients still showing 
symptoms of LVEF ≤ 35% and elevated natriure-
tic peptide levels (BNP ≥ 150 pg/ml or NT-pro-BNP 
≥ 600 pg/ml).
It is worth remembering, that all three management 
procedures can be freely combined.
At this point, a certain inaccuracy should be noted. In 
the registration of the European Medicines Agency (EMA) 
and thus in the summary of product characteristics, the 
indication for the including of ivabradine is a HR ≥ 75 bpm, 
whereas according to the guidelines of the European So-
ciety of Cardiology, this HR limit is ≥ 70 ppm. The results 
of the SHIFT subanalysis showed a significant benefit of 
including ivabradine in a subgroup of patients with resting 
pulse rate ≥ 75 bpm that is why these differences have 
shown up. However, it is expected that these indications 
will be harmonized [23, 32].
Treatment with ivabradine (Figure 2) usually starts 
with a dose of 5 mg 2 ×/24 h, after 2 weeks the dose 
can be increased to 7.5 mg 2 ×/24 h if the resting HR is 
consistently > 60 bpm, or reduced to 2.5 mg 2 ×/24 h 
(1/2 of 5 mg tablets 2 ×/24 h) if subjective bradycardia 
symptoms occur or if the HR decreases for a long time 
< 50 ppm. When HR is 50–60 ppm, a dose of 5 mg 
2 ×/24 h should be maintained. If during treatment, 
the HR at rest decreases permanently to < 50 bpm or if 
symptoms related to bradycardia appear, then in patients 
receiving a dose of 7.5 mg 2 ×/24 h or 5 mg 2 ×/24 h the 
dose should be reduced.
If the resting HR increases permanently to >60 bpm, 
patients receiving 2.5 mg 2 ×/24 h or 5 mg 2 ×/24 h 
may have their dose increased. Treatment should be dis-
continued if HR remains below 50 ppm or symptoms 
of bradycardia persist. In the elderly, an initial dose of 
2.5 mg 2 × 24 h should be considered. It is not necessary 
to modify the dosage in patients with creatinine clearan-
ce of > 15 ml/min. People with creatinine clearance of 
Figure 1. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure from 2016 — a part of the heart failure with 
reduced left ventricular ejection fraction (HFrEF) therapy algorithm — has been modified on the basis of (according to [32]); ACEI — an-
giotensin-converting enzyme inhibitor; LVEF — left ventricular ejection fraction; MRA — mineralocorticoid receptor antagonist/aldosterone 
antagonist; ARB — angiotensin II receptor antagonist /sartan; QRS — QRS complex width in electrocardiographic recording; HR — heart rate; 
ARNI — angiotensin receptor-neprilysin inhibitor; CRT — cardiac resynchronization therapy
Patients showing signs of HFrEF
Treatment with ACEI and the β-adrenolytic drug
(at maximum tolerable doses, proven to be effective in clinical trials)




(at maximum tolerable dose, proven to be effective in clinical trials)
Persistent symptoms and LVEF  35%
Tolerance of ACEI 
(or ARB)
Sinus rhythm, 
QRS   130 ms
Sinus rhythm, 
HR   70/min
ARNI instead of ACEI Ivabradine
Yes Yes Yes
Evaluate indications for CRT
Class I Class IIA
Yes Yes
The above methods of treatment can be combined with each other
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< 15 ml/min should be particularly cautious as there are 
no data on the safety of ivabradine in this group of patients.
There is no need to modify the dosage in patients 
with mild hepatic impairment, while in case of moderate 
disorders, caution should be paid [23].
The possibility of ivabradine use is of particular interest 
in patients in whom beta-adrenolytics should be avoided 
(in the case of 1st degree atrioventricular conduction block, 
peripheral vascular disease, bronchial asthma or severe 
chronic obstructive pulmonary disease). Unlike beta-adre-
nolytics, ivabradine can also be used in vasoconstrictive 
forms of angina, as it does not disturb the vasomotor 
balance of coronary vessels. Ivabradine also seems to 
be an important therapeutic option in patients receiving 
beta-adrenergic agonists with subsequent tachycardia, in 
middle-aged men who are particularly affected by potential 
sexual dysfunctions after the use of beta-block and in older 
patients with prolonged PR interval.
Studies with ivabradine
BEAUTIFUL study
The results of the BEAUTIFUL study were published in 
2008–2009. This study was intended to assess the effect 
of ivabradine added to the standard treatment of ischemic 
heart disease on mortality and morbidity from cardiovas-
cular causes. This was the first study with ivabradine 
with such large number of patients, involving more than 
10,000 patients with documented stable coronary artery 
disease, left ventricular systolic dysfunction (with ejection 
fraction < 40% and left ventricular end-diastolic dimen-
sion in the short axis > 56 mm) and resting sinus rhythm 
> 60 bpm. The primary complex endpoint included death 
caused by cardiovascular reasons and hospital treatment 
for acute myocardial infarction and new or acute heart 
failure. In addition, secondary endpoints included, total 
mortality, mortality due to ischemic heart disease and 
heart failure, and hospitalizations due to ischemic heart 
disease, HR or the need for revascularization. The study 
showed no difference in the prevalence of the primary 
complex endpoint in the ivabradine-treated group compa-
red to the placebo-treated group. However, in patients with 
HR ≥ 70 bpm, ivabradine significantly reduced the risk of 
myocardial infarction — by 36% (p < 0.001) and the risk 
of coronary revascularization — by 30% (p = 0.016) [33].
The analysis of patients with standard treatment 
(control group) showed that HR ≥ 70 bpm significan-
tly increased the risk of cardiovascular death by 34% 
(p = 0.0041), hospitalization caused by HF by 53% 
(p < 0.001), hospitalization cause by myocardial in-
farction by 46% (p = 0.0066) and coronary revasculari-
zation by 38% (p = 0.037). The increase in resting HR by 
every 5 bpm increased the risk of cardiovascular death 
by 8% (p = 0.0005), hospitalization cause by HF by 16% 
(p < 0.001), hospitalization for myocardial infarction by 
7% (p = 0.052) and coronary revascularization by 8% 
(p = 0.034). These results suggest that the risk of death 
and HF-related endpoint incidence increases continuou-
sly when HR > 70 bpm, while this relationship is less 
visible for coronary endpoints [34].
Figure 2. Dosage pattern of ivabradine in patients with heart failure (based on [25]); HR — heart rate
HR < 50 bpm HR 50–60 bpm HR > 60 bpm
Ivabradine 2 × 5 mg
(evaluation of HR after 14 days)
Ivabradine
2 × 2,5 mg
Ivabradine
2 × 5 mg
Ivabradine
2 × 7,5 mg
HR < 50 bpmHR > 60 bpmHR < 50 bpmHR > 60 bpmHR < 50 bpm
Ivabradine
2 × 5 mg
Ivabradine
2 × 7,5 mg
Ivabradine
2 × 2,5 mg
Ivabradine
2 × 5 mg
Discontinue the 
use of ivabradine
Attention! Treatment should be discontinued if after dose reduction to 2 × 2.5 mg/day the incidence 
of HR remains < 50/min or if symptoms of bradycardia persist, such as dizziness, tiredness or hypotension
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ASSOCIATE Study
The ASSOCIATE study showed that the combination of iva-
bradine and atenolol, has an additional anti-angina effect 
and improves the parameters of treadmill exercise test, 
without affecting the tolerance and safety of treatment. The 
study involved 889 patients with chronic stable coronary ar-
tery disease, receiving atenolol 50 mg/24 h, randomized to 
the group receiving 5 mg ivabradine, followed by 7.5 mg twice 
daily or a suitable placebo. The participants were tested 
three times: in the beginning, after 2 and 4 months of thera-
py. After 4 months in ivabradine group a significant increase 
in total exercise duration was observed (24.3 ± 65.3 s in 
ivabradine group when compared to 7.7 ± 63.8 s in placebo 
group; p < 0.001), time to decrease ST segment by 1 mm 
(45.7 ± 93 s in ivabradine group compared to 15.4 ± 86.6 s 
in placebo group; p < 0.001) and the time to development 
of signs of angina (49.1 ± 83.3 s and 22.7 ± 79.1 s, res-
pectively; p < 0.001) [35]. The results of this study and 
the results of the BEAUTIFUL study were the green light for 
the simultaneous use of beta-adrenolitics with ivabradine.
SHIFT study
It is known that increased HR is associated with worse 
prognosis in many cardiovascular diseases, including heart 
failure, and sometimes it is difficult to decrease the HR in 
many of these patients despite the use of beta-adrenolytics. 
The authors of the SHIFT study asked themselves whether 
adding ivabradine to the standard treatment of HR could re-
duce the number of hospitalizations of these patients [31].
All cardiologists have known the answer to this que-
stion since 2010. After 23 months of observation, a sig-
nificant (18%) reduction in the prevalence of the main 
endpoint, which consisted of cardiovascular causes of 
death and hospitalization due to decompensation of heart 
failure, was observed. Benefits were observed in practically 
all prospectively defined subgroups of patients. According 
to the analysis of individual components of the main end-
point, ivabradine reduces the risk of cardiovascular death 
by 9% (statistically insignificant difference) and reduces 
the risk of hospitalization due to decompensation of HR 
by 26% (p < 0.0001) [31].
The observation from the echocardiographic subana-
lysis of the SHIFT study is interesting, in which it turned 
out that ivabradine affects the remodeling and function of 
the left ventricular muscle. In the group of patients treated 
with ivabradine compared to placebo patients, a decrease 
in the left ventricular end-systolic volume index (LVESVI) by 
7 ± 16.3 was observed vs. 0.9 ± 17.1 ml/m2 (p < 0.001), 
reduction of left ventricular end-diastolic volume index 
(LVEDVI) by 7.9 ± 18.9 vs. 1.8 ± 19 ml/m2 (p = 0.002) and 
increase of LVEF by 2.4 ± 7.7 vs. 0.1 ± 8% (p < 0.001) [36].
At the beginning of this claim, the importance of an 
ageing population and the prognosis of an increasing 
number of patients with HR has been highlighted. Given 
that hospitalization is one of the strongest independent 
prognosis factors in heart failure, it worsens the quality 
of life, and from an economic point of view represents the 
most important part of the costs associated with treating 
heart failure. The reduction in the risk of hospitalization 
by more than 25% as a result of using ivabradine in the 
SHIFT study has been noted, and thus in clinical practice, 
it is of particular value.
SIGNIFY Study
The results of the study, which were announced in Sep-
tember 2014, were intended to assess whether the use 
of ivabradine and thus the reduction in HR would have an 
impact on the reduced morbidity and mortality in patients 
with stable coronary artery disease, with preserved left 
ventricular function and no clinical signs of heart failure.
The study involved 19 102 patients from over 
1139 centers. Patients aged ≥ 55 years, with stable co-
ronary artery disease, LVEF > 40%, with sinus rhythm of 
≥ 70 bpm and at least one risk factor of coronary artery 
disease were included to the study. Patients were ran-
domly assigned to the ivabradine group (9550 people) at 
a dose adjusted to achieve a resting HR of 55–60 bpm 
[(but the dose couldn’t exceed 10 mg/24 h (a dose of 
2 × 10 mg was not yet registered for use)] and to the 
placebo group [37].
Ivabradine decreased the resting HR by 10 beats per 
minute (9.7/min; 95% CI). However, over a period of almost 
28 months of observation, there were no differences in the 
incidence of a complex endpoint defined as cardiovascular 
death or non-fatal myocardial infarction between the two 
groups [6.8% (ivabradine) vs. 6.4% (placebo); p = 0.20; 
hazard ratio = 1.08].
SIGNIFY study results will not change the role of iva-
bradine in the therapy of heart failure, as the study applied 
to a different population of patients.
Everyone should be cautious and use their common 
sense when trying to pursuit the optimal HR, whereas the 
lower range of which is still unknown. As we know from 
experience, the golden mean is always the best.
ETHIC-AHF study
Increased HR is a disadvantageous prognostic factor when 
discharging a patient with heart failure. In some patients 
still in the hospital it may be useful to add ivabradine to 
the treatment with beta-adrenolytic. This type of strategy 
seems to be beneficial for patients with sinus rhythm 
and HR of ≥ 70 bpm, hospitalized once again due to HF 
exacerbation. Rehospitalization indicates that the current 
treatment strategy was ineffective and does not help us 
in avoiding of another rehospitalization without the modi-
fication of the therapy.
The aim of the ETHIC-AHF study was to evaluate the ef-
fect of early concomitant use of ivabradine (2 × 5–7.5 mg) 
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with beta-adrenolytic (bisoprolol or carvedilol) in compari-
son with monotherapy of beta-adrenolytic at the optimal 
dose (bisoprolol — 10 mg/day, carvedilol 50 mg/day) or at 
the maximum tolerated dose — control group, in patients 
with heart failure with reduced ejection fraction.
The authors analyzed the annual results of observa-
tions comparing these two treatment strategies in patients 
with sinus rhythm and HR of > 70 bpm [38]. 
71 patients were qualified for the study (33 in the 
study group and 38 in the control group). After 28 days 
the HR was lower in the study group (64.3 ± 7.5 vs. 
70.3 ± 9.3 bpm, p = 0.01), and this difference per-
sisted also after one year of therapy (61.8 ± 5.5 vs. 
68.4 ± 9.3 bpm, p = 0.01). Doses of beta-adrenolytics 
were similar in both groups [38].
Left ventricular ejection fraction was significantly 
higher in the study group (48.2 ± 17 vs. 41.8 ± 10%, 
p = 0.002). The risk of cardiovascular death was 26% 
lower in the ivabradine group, but in comparison with the 
control group statistical significance was not achieved [38].
Despite the fact that ETHIC-AHF was a small clinical 
trial, it was shown that intensification of treatment is par-
ticularly important during the period of highest sensitivity 
after hospitalization — during the first 30 days, while simul-
taneous administration of beta-adrenolytic and ivabradine 
to patients stabilized after decompensation, results in 
a significant decrease in HR and improvement of the LVEF, 
both in short and long term observation [38].
Summary
The profile of a patient with HR has changed significantly in 
recent years. Today’s patients have do not only have diffe-
rent clinical characteristics, but also different needs than 
those treated a few years ago. Currently, there is a need 
for drugs that not only reduce the risk of death in patients 
with heart failure, but also have beneficial effects on the 
risk of repeated hospitalizations, normalizing hemodyna-
mic parameters and improving the tolerance of exercise. 
Ivabradine turned out to be such a drug, which not only 
significantly reduces HR but also positively affects all the 
above-mentioned parameters, at the same time being 
the most modern form of treatment in patients with heart 
failure. Only further optimization of pharmacotherapy — 
especially with drugs with a well-proven beneficial effect 
on patient prognosis — can contribute to the improvement 
of long-term survival in this group.
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Streszczenie
Przyspieszona częstość rytmu serca stanowi czynnik ryzyka śmiertelności ogólnej oraz sercowo-naczyniowej w różnych 
populacjach pacjentów. Stosowanie klasycznych leków zwalniających rytm serca, takich jak beta-adrenolityki czy anta-
goniści wapnia z grupy niedihydropirydynowych (werapamil i diltiazem), jest często ograniczone z powodu ich działań 
niepożądanych. Iwabradyna jest unikatowym, nowoczesnym lekiem, którego mechanizm działania polega na blokowaniu 
prądu If w węźle zatokowo-przedsionkowym. Przekłada się to na zmniejszenie częstości rytmu serca — parametru zwią-
zanego z niekorzystnym rokowaniem u pacjentów z niewydolnością serca (HF). Niniejszy dokument stanowi opinię grupy 
ekspertów będącą podsumowaniem aktualnej wiedzy dotyczącej iwabradyny i jej zastosowania w populacji chorych z HF.
Słowa kluczowe: optymalizacja terapii, niewydolność serca, iwabradyna
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